Replimune Group, Inc. (REPL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$15.04-1.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · REPL
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||||
| Selling, General & Admin | — | 98.7 | — | — | — | — | — | — | — |
| R&D Expenses | 212.6 | 221.2 | 189.4 | 175.0 | 126.5 | 79.5 | 56.8 | 38.8 | 38.8 |
| Operating Income | (297.7) | (319.9) | (261.6) | (234.8) | (177.1) | (118.3) | (80.0) | (56.2) | (56.2) |
| Earnings from Continuing Operations | |||||||||
| Other Non-Operating Income / Expenses | 0.2 | 5.4 | 14.8 | 19.4 | 3.1 | 0.3 | (0.9) | 3.6 | 3.6 |
| EBT, Incl. Unusual Items | — | (314.5) | (246.8) | (215.4) | (174.0) | (118.0) | (80.9) | (52.6) | (52.6) |
| Income Tax Expense | — | (0.6) | 0.5 | 0.4 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||
| Net Income | (297.0) | (313.9) | (247.3) | (215.8) | (174.3) | (118.0) | (80.9) | (52.6) | (52.6) |
| Per Share | |||||||||
| Basic EPS | (3.07) | (3.38) | (3.07) | (3.24) | (2.99) | (2.26) | (1.75) | — | — |
| Diluted EPS | (3.07) | (3.38) | (3.07) | (3.24) | (2.99) | (2.26) | (1.75) | — | — |
| Basic Weighted Avg Shares | 96.9 | 92.8 | 80.6 | 66.6 | 58.2 | 52.2 | 46.2 | — | — |
| Diluted Weighted Avg Shares | 96.9 | 92.8 | 80.6 | 66.6 | 58.2 | 52.2 | 46.2 | — | — |
| Supplemental | |||||||||
| EBITDA | — | (316.6) | (258.1) | (232.1) | (174.6) | (116.2) | (78.2) | (55.7) | (55.7) |
| EBIT | (297.7) | (319.9) | (261.6) | (234.8) | (177.1) | (118.3) | (80.0) | (56.2) | (56.2) |
| Effective Tax Rate | — | — | — | — | -0.2% | 0.0% | 0.0% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.